Clinical Trial Update: Bioequivalence Fasting Study in Patients [Phase 2, Phase 3]

View source ↗

Summary

Amneal conducted a fasting-state bioequivalence study in schizophrenia patients; the Phase 2/3 trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Amneal Pharmaceuticals, LLC | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED